Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. It is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. It is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 70.79% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 62.38M.
Undervalued
The company’s latest PE is -35.49, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 177.88M shares, increasing 16.78% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 20.37K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.63.